BioNexus Gene Valuation
| BGLC Stock | USD 2.28 0.08 3.64% |
Based on Macroaxis valuation methodology, the firm appears to be overvalued. BioNexus Gene Lab shows a prevailing Real Value of $2.11 per share. The current price of the firm is $2.28. Our model approximates the value of BioNexus Gene Lab from analyzing the firm fundamentals such as Return On Equity of -0.28, profit margin of (0.24) %, and Current Valuation of 2.35 M as well as examining its technical indicators and probability of bankruptcy. Key fundamental drivers impacting BioNexus Gene's valuation include:
Price Book 0.7421 | Enterprise Value | Enterprise Value Ebitda 629.5269 | Price Sales 0.5494 | Enterprise Value Revenue 0.248 |
Overvalued
Today
Please note that BioNexus Gene's price fluctuation is very risky at this time. Calculation of the real value of BioNexus Gene Lab is based on 3 months time horizon. Increasing BioNexus Gene's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Since BioNexus Gene is currently traded on the exchange, buyers and sellers on that exchange determine the market value of BioNexus Stock. However, BioNexus Gene's intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 2.28 | Real 2.11 | Hype 2.36 |
The real value of BioNexus Stock, also known as its intrinsic value, is the underlying worth of BioNexus Gene Lab Company, which is reflected in its stock price. It is based on BioNexus Gene's financial performance, growth prospects, management team, or industry conditions. The intrinsic value of BioNexus Gene's stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, or news.
Estimating the potential upside or downside of BioNexus Gene Lab helps investors to forecast how BioNexus stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of BioNexus Gene more accurately as focusing exclusively on BioNexus Gene's fundamentals will not take into account other important factors: Traditionally, analysts and sophisticated investors use multiple methods for valuing a cash-flow-generating entity or its stock. For example, some money managers use BioNexus Gene's intrinsic value based on its ongoing forecasts of BioNexus Gene's financial statements. In contrast, other private, professional wealth advisors use a multiplier approach by looking to relative value analysis against BioNexus Gene's closest peers. If more than one evaluation category is relevant for BioNexus Gene we suggest using both methods to arrive at a better estimate.
BioNexus Gene Cash |
|
About BioNexus Gene Valuation
The stock valuation mechanism determines BioNexus Gene's current worth on a weekly basis. Our valuation model uses a comparative analysis of BioNexus Gene. We calculate exposure to BioNexus Gene's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of BioNexus Gene's related companies.| Last Reported | Projected for Next Year | ||
| Gross Profit | 1.5 M | 1.1 M | |
| Pretax Profit Margin | (0.15) | (0.16) | |
| Operating Profit Margin | (0.15) | (0.16) | |
| Net Loss | (0.15) | (0.16) | |
| Gross Profit Margin | 0.16 | 0.28 |
BioNexus Gene Growth Indicators
Growth stocks usually refer to those companies expected to grow sales and earnings faster than the market average. Growth stocks typically don't pay dividends, often look expensive, and usually trading at a high P/E ratio. Nevertheless, such valuations could be relatively cheap if the company continues to grow, which will drive the share price up. However, since most investors are paying a high price for a growth stock, based on expectations, if those expectations are not fully realized, growth stocks can see dramatic declines.
| Common Stock Shares Outstanding | 1.8 M | |
| Quarterly Earnings Growth Y O Y | -0.95 |
BioNexus Gene Current Valuation Indicators
Valuation refers to the process of determining the present value of BioNexus Gene Lab and all of its assets. It can be calculated using a number of techniques. As many analysts who try to value BioNexus we look at many different elements of the entity such as BioNexus's management, its prospective future earnings, the current market value of the company's assets, as well as its capital structure formation.
Valuations are an essential part of business, for companies themselves, but also for investors. For companies, such as BioNexus Gene, valuations can help measure their progress and success and can help them track their performance in the market compared to others. In addition, investors can use BioNexus Gene's valuations to help determine the worth of potential investments. They can do this by using data and information made public by a company. Regardless of who the valuation is for, it essentially describes BioNexus Gene's worth.Complementary Tools for BioNexus Stock analysis
When running BioNexus Gene's price analysis, check to measure BioNexus Gene's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy BioNexus Gene is operating at the current time. Most of BioNexus Gene's value examination focuses on studying past and present price action to predict the probability of BioNexus Gene's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move BioNexus Gene's price. Additionally, you may evaluate how the addition of BioNexus Gene to your portfolios can decrease your overall portfolio volatility.
| Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios | |
| Sync Your Broker Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors. | |
| Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets | |
| Content Syndication Quickly integrate customizable finance content to your own investment portal | |
| Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals | |
| Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities | |
| Fundamental Analysis View fundamental data based on most recent published financial statements | |
| Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk | |
| Global Correlations Find global opportunities by holding instruments from different markets |